NEW YORK, July 8 — 1%. That figure that matters: melanoma accounts for about 1% of all skin cancers, yet it causes the majority of skin cancer deaths. By the numbers, the American Cancer Society projects an estimated 100,640 new melanomas will be diagnosed in the U.S. in 2024, with roughly 8,290 deaths.
The bottom line: a tiny fraction of cases carries an outsized fatality rate. Now, a compound from an unlikely source — the Antarctic sea squirt — has been found to kill melanoma cells.
Researchers collected the marine organism during an expedition to Antarctica. The discovery opens a new avenue for melanoma therapy, though the exact mechanism by which the compound works is not detailed in the source material. The compound’s potential as a treatment is under active investigation.
The sea squirt, a marine organism that lives in Antarctic waters, produces the compound. Scientists on the expedition brought samples back for laboratory analysis.
Melanoma arises from melanocytes, the pigment-producing cells in the skin. The American Cancer Society reports that while melanoma is relatively rare by incidence, its lethality makes it a persistent target for drug developers. The Antarctic discovery represents a fundamentally different chemical starting point.
Marine organisms have historically yielded useful compounds — the source material notes the sea squirt’s compound kills melanoma cells, though it does not specify the concentration or experimental conditions. The compound is under investigation, meaning years of preclinical and clinical work likely lie ahead before any potential human use. No timeline for trials is provided in the source material.
The discovery team has not been named in the available information. For context, the 2024 U.S. melanoma numbers — 100,640 new cases and 8,290 deaths — underscore the medical need.
Even a 1% cancer type, by the numbers, represents tens of thousands of lives affected annually. The compound’s mechanism remains unspecified in the source. That is typical for early-stage natural product discovery: researchers often isolate a bioactive compound before fully understanding how it works.
The Antarctic sea squirt’s ability to produce a melanoma-killing molecule in its extreme environment adds to the growing library of marine-derived drug candidates. Investors and researchers alike will watch for further data releases.
The next milestones would likely include identification of the compound’s structure, its mechanism of action, and animal-model testing. None of that detail is available from the source material at this time. The bottom line: a 1% cancer that causes the majority of skin cancer deaths now has a potential new lead from an unexpected source.
The science is early, but the direction is clear. Consult your doctor for medical advice.
